SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

Centessa Pharmaceuticals Announces Orphan Drug Designation Granted To SerpinPC For Treatment Of Hemophilia B

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop, and ultimately

Benzinga · 09/14/2022 09:02

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC, a novel inhibitor of activated protein C ("APC"), for the treatment of hemophilia B. Centessa plans to begin registrational studies of SerpinPC in the fourth quarter of 2022.